COMPARISON TOOL

Semaglutide vs Tirzepatide vs Retatrutide

One, two, and three receptors. Semaglutide is the reference GLP-1, tirzepatide adds GIP, and retatrutide adds glucagon — each step has meant more weight loss in trials, with the same family of side effects.

SemaglutideTirzepatideRetatrutide

Max 4 peptides

Property	Semaglutide	Tirzepatide	Retatrutide
Category	GLP-1	GLP-1	GLP-1
Type	Peptide	Peptide	Peptide
Mechanism	GLP-1 receptor agonist	Dual GIP / GLP-1 receptor agonist	Triple agonist (GLP-1 / GIP / glucagon)
Status	FDA-approved	FDA-approved	Phase 3
Dosing range	0.25–2.4 mg weekly	2.5–15 mg weekly	1–12 mg weekly
Frequency	Once weekly	Once weekly	Once weekly
Half-life	~7 days	~5 days	~6 days
Route	Subcutaneous	Subcutaneous	Subcutaneous
Onset	1–4 weeks for appetite reduction	1–4 weeks for appetite reduction	1–4 weeks for appetite reduction
Studied for	Weight management Type 2 diabetes Appetite control Cardiovascular risk	Weight management Type 2 diabetes Appetite control	Weight management Liver fat reduction Appetite control Energy expenditure
Key risks	Nausea Vomiting Diarrhea Constipation	Nausea Vomiting Diarrhea Constipation	Nausea Vomiting Diarrhea Constipation Modest heart-rate increase
Storage	Refrigerated (2–8 °C); use within the pharmacy beyond-use date	Refrigerated (2–8 °C); use within the pharmacy beyond-use date	Refrigerated (2–8 °C); use within the pharmacy beyond-use date
Available at G1	Not currently carried. Ask a provider	Not currently carried. Ask a provider	Vials: 10 mgShop →
Tools	Dosage calculator →	Dosage calculator →	Dosage calculator →

PROPERTY COMPARISON · RADAR

Profile shape

Editorial profile scores (0–10) for orientation — not clinical measurements.

TYPICAL DOSE RANGES

Dose envelope

Semaglutide250 mcg – 2.4 mg

Tirzepatide2.5 mg – 15 mg

Retatrutide1 mg – 12 mg

Typical per-dose range on a logarithmic scale. Your provider sets your dose.

For educational purposes only. Consult a licensed provider before starting any peptide protocol.